SCHEMBL268409

SCHEMBL268409

CCN(CC)CCN(C)Cc1cccc(C(=O)Nc2ccc(N3CCOCC3)cc2C(=O)N/N=C\c2ccc(Cl)c(C(F)(F)F)c2)c1

nearest known ligand 0.55

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SLC34A2 O95436 11/20 0.55
ALDH1A1 P00352 6/20 0.44
RAF1 P04049 1/20 0.41
KDM4E B2RXH2 7/20 0.40
MAPT P10636 6/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
PKM P14618 1/20 0.40
RAB9A P51151 1/20 0.40
HPGD P15428 2/20 0.39
LMNA P02545 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
POLB P06746 1/20 0.39
SLC34A1 Q06495 1/20 0.37
SLC34A3 Q8N130 1/20 0.37
SLC20A1 Q8WUM9 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL268410 1.00 SLC34A2 (0.55) SLC34A2ALDH1A1RAF1KDM4EMAPT
SCHEMBL274665 1.00 SLC34A2 (0.55) SLC34A2ALDH1A1RAF1KDM4EMAPT
SCHEMBL267819 0.94 SLC34A2 (0.56) SLC34A2ALDH1A1RAF1KDM4EMAPT
SCHEMBL274157 0.94 SLC34A2 (0.56) SLC34A2ALDH1A1RAF1KDM4EMAPT
SCHEMBL267818 0.94 SLC34A2 (0.56) SLC34A2ALDH1A1RAF1KDM4EMAPT
SCHEMBL266052 0.94 SLC34A2 (0.56) SLC34A2ALDH1A1RAF1KDM4EMAPT
SCHEMBL274630 0.94 SLC34A2 (0.56) SLC34A2ALDH1A1RAF1KDM4EMAPT
SCHEMBL266053 0.94 SLC34A2 (0.56) SLC34A2ALDH1A1RAF1KDM4EMAPT
SCHEMBL267922 0.93 SLC34A2 (0.56) SLC34A2ALDH1A1RAF1KDM4EHPGD
SCHEMBL267923 0.93 SLC34A2 (0.56) SLC34A2ALDH1A1RAF1KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-09-28 US disclosed
EP-1614676-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2006-01-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same SLC10A6, SLC7A1, SLC10A1 SLC34A2 6/4885ALDH1A1 3022/4885RAF1 1655/4885
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 SLC34A2 2/4885ALDH1A1 2872/4885RAF1 1766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.